Bifunctional PROTAC Compounds for Targeted Protein Degradation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing small molecule therapeutics face challenges in effectively targeting E3 ubiquitin ligases for protein degradation due to the difficulty in disrupting protein-protein interactions, particularly for therapeutic indications like cancer and chronic anemia.
Innovation Solution
Development of bifunctional compounds, known as PROTACs, that recruit target proteins to E3 ubiquitin ligases for ubiquitination and subsequent degradation by linking a VHL ligand to a protein-binding moiety, facilitating the proximity-induced ubiquitination and proteasomal degradation of specific proteins.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If small molecule drugs are used to target E3 ubiquitin ligases, then therapeutic specificity is improved, but the ability to effectively disrupt protein-protein interactions deteriorates
Solution Approach 1:
The compound is divided into two distinct functional domains: a VHL ligase binding domain and a target protein binding domain. This segmentation allows each domain to independently perform its specific function - the VHL domain provides E3 ligase targeting while the other domain provides substrate recognition, together enabling effective protein-protein interaction disruption that neither domain could achieve alone
Solution Approach 2:
The bifunctional compound acts as an intermediary molecule that bridges the VHL E3 ubiquitin ligase and the target protein. By containing both binding moieties in a single molecule, it mediates the interaction between these two proteins, facilitating their proximity-induced ubiquitination and degradation while maintaining therapeutic specificity
2Productivity
If bifunctional compounds are developed to recruit proteins to E3 ligases, then protein degradation efficacy is improved, but device complexity increases
Solution Approach 1:
Two separate functional components (VHL ligase binder and target protein binder) are merged into a single bifunctional compound. This combining approach enables the compound to simultaneously engage both the E3 ligase and the target protein, achieving effective protein degradation while managing complexity through rational molecular design rather than using separate compounds or complex delivery systems
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The PROTAC compounds enable targeted protein degradation, providing a therapeutic approach for diseases modulated by specific protein activity, demonstrating potential in treating conditions such as cancer and chronic anemia.
Implementation Method 1
the VHL ligand, which binds to the VHL E3 ubiquitin ligase
Implementation Method 2
recruit target proteins to E3 ubiquitin ligases for ubiquitination and subsequent degradation
Implementation Method 3
subsequent degradation by the proteasome
Data Source
AI summary
The present invention relates to bifunctional compounds, which find utility as modulators of targeted ubiquitination, especially inhibitors of a variety of polypeptides and other proteins which are degraded and/or otherwise inhibited by bifunctional compounds according to the present invention. In particular, the present invention is directed to compounds, which contain on one end a VHL ligand which binds to the ubiquitin ligase and on the other end a moiety which binds a target protein such that the target protein is placed in proximity to the ubiquitin ligase to effect degradation (and inhibition) of that protein. The present invention exhibits a broad range of pharmacological activities associated with compounds according to the present invention, consistent with the degradation/inhibition of targeted polypeptides.